Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... It is just, it’s Moderna-like… in the money they throw in the chimney.” CRISPR (NASDAQ:CRSP) develops ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...

Moderna provides updates on its business and ... three regulatory filings seeking the FDA’s approval. Intellia Therapeutics announced its strategic priorities and key anticipated milestones ...